HoneyBear Biosciences Inc. (hereinafter referred to as HoneyBear) exclusively owns and has multiple patents for the CoNectarTM technology platform, which is gradually drawing attention from international peers. The company’s CEO, Dr. Chuang, Simon, Shih-Hsien, was invited to Singapore to give a keynote speech at the ADC Congress Asia on March 12th, 2025. On the same day, he and Sarina Lin, Vice Chairwoman of HoneyBear, attended the awarding ceremony as the winner of 2025 Asia Pacific Biopharma Excellence Awards (ABEA) and awarded as the ‘Best ADC Developer in Taiwan.’
As the inventor of the CoNectarTM technology platform, Dr. Chuang has been invited to present his remarkable research results at many international ADC conferences. In his keynote speech at the ADC Congress Asia, he has presented the latest animal study results on Antibody Radionuclide Conjugates (ARC), it’s the first time to introduce such data in Asia. He mentioned, ‘Through the support of such groundbreaking research results, combining with the feasibility of CoNectarTM platform, which is able to provide the diversity and flexibility of antibody drug conjugate mix; we can develop ADCs with more precise control over drug dosage, efficacy, and safety through such powerful ADC technology. Therefore, HoneyBear plans to expand its product pipeline and accelerate new drug development through technology licensing.’
The research results reflected that the ADCs developed by CoNectarTM platform would have potential to be superior to the current market available ADCs or some other ADCs under development. Also, it may support developing more breakthrough ADCs to bring new hope for hard-to-treat cancers; moreover, it may go for extra mile to be applied to some other clinical treatments in the future.
In addition, HoneyBear won the 2025 Asia Pacific Biopharma Excellence Awards (ABEA) competition and was recognized as the ‘Best ADC Developer in Taiwan’. The awarding ceremony was held at 7 PM of March 12, 2025, at the Sands Expo & Convention Centre, Singapore.
Sarina said: ‘HoneyBear is a rising star in the biotech industrial territory. We’ve just completed the fundraising in November 2024, receiving high recognition and substantial investments from venture capital firms and investors. Our R&D team and our professional leadership team, with expertise in drug manufacturing, business management, and marketing etc., ensure the company is managed by an A team so HoneyBear’s performance will be even more noticeable thereafter. In the future, we will continue to focus on R&D and plan to complete the first Investigational New Drug (IND) clinical trial application by 2026, officially joining in the rank of new drug development.’
She added: ‘As we’re continuously and rapidly demonstrating excellent results, we believe more investments will flow in to reinforce the company’s operational efficiency and support Honeybear to get exposure in the global market.’
Introduction of HoneyBear Biosciences Inc.
HoneyBear Biosciences, Inc is a Taiwan-based biotech company that is leveraging its proprietary antibody-drug conjugation platform – CoNectar™ – for global drug development. Founded in 2021, HoneyBear Biosciences, Inc is a Taiwan-based biotech company targeting the global pharmaceutical market. We strive to develop new antibody technologies to deliver novel therapeutics to cancer patients. Our business strategy consists of utilizing our powerful antibody engineering platforms to develop and commercialize novel Antibody-Drug Conjugates (ADC) through licensing and co-development partnership with biotech and pharmaceutical companies.
Website: HoneyBear Biosciences, Inc
